Boston Scientific Corporation
NYSE:BSX · New York Stock Exchange
+$0.45 today
Vol 30.83M · Avg 19.45M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:BSX · Revenue to Net Income
Key Ratios
Analysis
$20.6B of revenue converted into $3.6B of net income for the selected period. Gross margin is 70.4% and net margin is 17.2%, showing how much revenue survives after costs and taxes. EPS is $2.38, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.1B +19.9% | $16.7B +17.6% | $14.2B +12.3% | $12.7B +6.7% | $11.9B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $6.2B -4.0% | $6.5B +19.8% | $5.4B +8.9% | $5.0B +12.2% | $4.4B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $13.9B +34.9% | $10.3B +16.3% | $8.8B +14.5% | $7.7B +3.4% | $7.5B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 69.0% +7.7pp | 61.3% -0.7pp | 62.0% +1.2pp | 60.8% -1.9pp | 62.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $2.1B +27.1% | $1.6B +14.2% | $1.4B +6.9% | $1.3B +9.9% | $1.2B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $6.9B +15.1% | $6.0B +15.3% | $5.2B +14.8% | $4.5B +5.5% | $4.3B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $9.9B +29.5% | $7.6B +14.8% | $6.7B +12.9% | $5.9B +6.3% | $5.5B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.4B +7.8% | $1.3B +6.1% | $1.2B +5.3% | $1.1B +3.9% | $1.1B | $374.2M | $1.2B | $631.8M |
| EBITDA | $5.1B +29.6% | $3.9B +14.0% | $3.5B +26.0% | $2.7B +8.9% | $2.5B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 25.4% +1.9pp | 23.5% -0.7pp | 24.2% +2.6pp | 21.6% +0.4pp | 21.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $4.0B +50.7% | $2.6B +20.8% | $2.2B +19.6% | $1.8B -5.1% | $1.9B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 19.8% +4.0pp | 15.7% +0.4pp | 15.3% +0.9pp | 14.4% -1.8pp | 16.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $107.0M +386.4% | $22.0M +120.0% | $10.0M +150.0% | $4.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $349.0M -9.8% | $387.0M +42.3% | $272.0M -41.4% | $464.0M +33.0% | $349.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$586.0M -66.0% | -$353.0M -80.1% | -$196.0M +71.3% | -$683.0M +19.3% | -$846.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $3.4B +48.3% | $2.3B +15.0% | $2.0B +74.0% | $1.1B +6.0% | $1.1B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 16.9% +3.2pp | 13.6% -0.3pp | 13.9% +4.9pp | 9.0% -0.1pp | 9.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $493.0M +13.1% | $436.0M +10.9% | $393.0M -11.3% | $443.0M +1130.6% | $36.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $2.9B +55.7% | $1.9B +16.4% | $1.6B +128.2% | $698.0M -32.9% | $1.0B | $4.9B | $4.8B | $4.7B |
| Net Margin | 14.4% +3.3pp | 11.1% -0.1pp | 11.2% +5.7pp | 5.5% -3.2pp | 8.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +55.6% | $1 +16.6% | $1 +140.8% | $0 -35.2% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +55.2% | $1 +16.5% | $1 +140.6% | $0 -35.1% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.5B +0.6% | $1.5B +1.3% | $1.5B +1.6% | $1.4B +0.6% | $1.4B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.5B +0.6% | $1.5B +1.5% | $1.5B +1.7% | $1.4B +0.4% | $1.4B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Amgen Inc.
NASDAQ:AMGN
$181.01B
Abbott Laboratories
NYSE:ABT
$153.82B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.65B
Pfizer Inc.
NYSE:PFE
$144.22B
Danaher Corporation
NYSE:DHR
$126.07B
Stryker Corporation
NYSE:SYK
$119.35B
Medtronic plc
NYSE:MDT
$101.66B
Sanofi
NASDAQ:SNY
$101.44B
McKesson Corporation
NYSE:MCK
$87.60B
HCA Healthcare, Inc.
NYSE:HCA
$83.16B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BSX generate?
Boston Scientific Corporation (BSX) reported $20.07B of revenue in fiscal 2025.
Is BSX profitable?
Boston Scientific Corporation (BSX) reported $2.89B of net income, with a net margin of 14.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.